Quantcast

Latest autoimmune disorders Stories

2011-06-28 11:30:00

ROCKVILLE, Md., June 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

2011-04-28 12:02:00

ROCKVILLE, Md., April 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART(TM) antibody technology. Included in the peer-reviewed article titled, "Application of...

2010-07-15 05:00:00

ROCKVILLE, Md., July 15 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

2009-09-07 14:39:01

Findings reveal further detail about protein linked to inflammatory disorders.

2009-06-15 07:30:00

Findings Published in Nature Medicine Suggest Broad Implications for the Treatment of Inflammatory and Autoimmune Disorders SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- Proteolix, Inc.

2009-06-04 14:11:02

A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI), along with the Harvard School of Dental Medicine.

2009-03-26 08:58:00

ROCKVILLE, Md., March 26 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Eric Risser as Vice President, Business Development.

2008-07-31 06:00:00

By Euna Lhee, The Baltimore Sun Jul. 31--Maryland researchers have identified a key receptor in the intestine that can trigger celiac disease, and they hope their findings can be applied to other autoimmune disorders, such as Type 1 diabetes and multiple sclerosis.


Word of the Day
abactinal
  • Pertaining to the surface or end opposite to the mouth in a radiate animal.
The word 'abactinal' comes from a Greek root meaning 'ray' and a Latin prefix meaning 'away'.
Related